Allogene Therapeutics Inc [ALLO] stock is trading at $1.68, up 9.09%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ALLO shares have gain 4.35% over the last week, with a monthly amount glided 15.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on March 14, 2025, when Citizens JMP upgraded its rating to a Mkt Outperform but kept the price target unchanged to $5 for it. On May 31, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $11 on the stock. JMP Securities downgraded its rating to a Mkt Perform. Guggenheim downgraded its rating to a Neutral. Citigroup started tracking with a Buy rating for this stock on December 08, 2023, and assigned it a price target of $7. In a note dated December 08, 2023, Citigroup initiated an Buy rating.
Allogene Therapeutics Inc [ALLO] stock has fluctuated between $1.23 and $3.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.68 at the most recent close of the market. An investor can expect a potential return of 1626.19% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
Allogene Therapeutics Inc [NASDAQ:ALLO] reported sales of 0.02M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -326.23% with Operating Profit Margin at -12191.36%, Pretax Profit Margin comes in at -11688.5%, and Net Profit Margin reading is -11708.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.55 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5600 points at the first support level, and at 1.4400 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7500, and for the 2nd resistance point, it is at 1.8200.
Ratios To Look Out For
For context, Allogene Therapeutics Inc’s Current Ratio is 8.54. Also, the Quick Ratio is 8.54, while the Cash Ratio stands at 2.12. Considering the valuation of this stock, the price to sales ratio is 18250.36, the price to book ratio is 0.84.
Transactions by insiders
Recent insider trading involved Yoshiyama Annie, SVP, Finance, that happened on Apr 21 ’25 when 9601.0 shares were sold. Officer, Yoshiyama Annie completed a deal on Apr 21 ’25 to buy 9601.0 shares. Meanwhile, President and CEO Chang David D sold 46668.0 shares on Mar 14 ’25.
